American Journal of Cardiovascular Disease Research
ISSN (Print): ISSN Pending ISSN (Online): ISSN Pending Website: Editor-in-chief: Dario Galante
Open Access
Journal Browser
American Journal of Cardiovascular Disease Research. 2014, 2(2), 17-22
DOI: 10.12691/ajcdr-2-2-1
Open AccessArticle

Viscum Album Versus Bleomycin for Pleurodesis among Patients with Malignant Pleural Effusion

Marawan H. Elkasas1 and Hamdy D. Elayouty1,

1Cardiothoracic Surgery Department, Suez Canal University, Ismailia, Egypt

Pub. Date: May 20, 2014

Cite this paper:
Marawan H. Elkasas and Hamdy D. Elayouty. Viscum Album Versus Bleomycin for Pleurodesis among Patients with Malignant Pleural Effusion. American Journal of Cardiovascular Disease Research. 2014; 2(2):17-22. doi: 10.12691/ajcdr-2-2-1


OBJECTIVE: To compare between mistletoe(Viscum album) and bleomycin as chemical agents for pleurodesis in malignant pleural effusions. METHODS: In this study 50 patients with pathologically confirmed, symptomatic, malignant pleural effusion irrespective of the primary tumor were studied at Suez Canal University hospital in the period of 3 years from January 2009 to December 2012. Patients were divided into 2 groups; 25 patients each: group A(pleurodesis with Mistletoe using 100mg – 5 ampoules-repeated two or three times, injected every other day) and group B(pleurodesis with Bleomycin1 iu/kg average-4 ampoules-or maximally 60 units). follow-up included postero-anterior and lateral chest radiography done after one week, month and 3 months. RESULTS: Most of the patients among both groups show complete remission defined as no effusion detected within four weeks of pleurodesis (72% and 56% among bleomycin and Viscum groups respectively). Significant difference was found between both groups. Recurrences were more frequent among group A (20% versus 8% in group B), P < 0.05. Hospital stay was shorter in the bleomycin group of patients, with a mean of (6.2) day. CONCLUSION: Both bleomycin and Viscum album are effective and safe agents for chemical pleurodesis, however bleomycin has some advantages over Viscum album due to its lower incidence of failure, and being more economic and for the shorter hospital stay.

Viscum album malignant pleural effusion mistletoe bleomycin pleurodesis

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Sahn SA: The differential diagnosis of pleural effusions. West J Med 1982 Aug; 137: 99-108.
[2]  Lynch TJ.: Management of malignant pleural effusions. Chest 1993; 103(suppl): 385S-389S.
[3]  Sahn SA: Malignancy metastatic to the pleura. Clin Chest Med. 1998 Jun; 19(2): 351-61.
[4]  F. Rodriguez-Panadero, V.B. Antony: Pleurodesis: state of the art. Eur Respir J 1997; 10: 1648-1654.
[5]  Walker-Renard P, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 1994; 120: 56-64.
[6]  Ruckdeschel JC, Moores D, Lee JY, et al. Intrapleural therapy for malignant pleural effusions. A randomized comparison of bleomycin and tetracycline. Chest 1991; 100: 1528-35.
[7]  Zimmer PW, Mark H, Kenneth C, Eric H and Low DE. Prospective Randomized Trial of Talc Slurry vs Bleomycin in Pleurodesis for Symptomatic Malignant Pleural Effusions.Chest 1997; 112; 430-434.
[8]  Diacon AH, Wyser C, Bolliger CT, et al. Prospective randomized comparison of thoracoscopic talc poudrage under local anesthesia versus bleomycin instillation for pleurodesis in malignant pleural effusions. Am J Respir Crit Care Med 2000; 162: 1445-1449.
[9]  Robinson LA, Fleming W7H, Galbraith TA. Intrapleural doxycycline control of malignant pleural effusions. Ann Thorac Surg 1993; 55: 1115-22.
[10]  Patz EF Jr, McAdams, P, Erasmus, JJ, et al: Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage.Chest1998; 113, 1305-1311.
[11]  Antony VB, Rothfuss KJ, Godbey SW, Sparks JA, Hott JW. Mechanism of tetracycline hydrochloride-induced pleurodesis: tetracycline hydrochloride-stimulated mesothelial cells produce a growth factor-like activity for fibroblasts. Am Rev Respir Dis 1992; 146: 1009-1013.
[12]  Vargas FS, Wang N-S, Lee HM, Gruer SE, Sassoon CSH, Light RW.: Effectiveness of bleomycin in comparison to tetracycline as pleural sclerosing agent in rabbits. Chest 1993; 104: 1582-1584.
[13]  Kienle G. S., Kiene H: Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic Mistletoe extracts. Eur J Med Res (2007) 12: 103-119.
[14]  Molassiotis A. , Fernandez-Ortega P., Pud D., et al.: Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 2005; 16: 655-663.
[15]  Kienle GS, Berrino F, Büssing A, Portalupi E, Rosenzweig S, Kiene H.: Mistletoe in Cancer a Systematic Review on Controlled Clinical Trails. European Journal of Medical Research 2003; 8: 109-19.
[16]  Horneber M, Bueschel G, Huber R, Linde K, Rostock M.: Mistletoe therapy in oncology. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD003297.
[17]  Becker H.: European mistletoe: Taxonomy, host trees, parts used, physiology. In: Büssing A editor(s). Mistletoe: The Genus Viscum. Harwood Academic Publishers, 2000:31-41.
[18]  Kim M-H, Park Y-K, Lee S-H, et al: Comparative study on the effects of a Viscum album (L.) extract (mistletoe) and doxycycline for pleurodesis in patients with malignant pleural effusion. Translation by Helixor Heilmittel GmbH. Korean Journal of Medicine 1999, 57:S121.
[19]  Stump P C and A. Büssing: Stimulation of antitumour immunity by intrapleural instillation of a Viscum album L. extract. Anti cancer drugs 1997, 8 (suppl 1) S23-S26.
[20]  Stirpe F., Sandvig K., Olsnes S., Pihl A. Action of viscumin, a toxic lectin from mistletoe, on cells in culture . J Biol Chem. 1982; 257: 13271-13277.
[21]  Klein R, Classen K, Berg PA, Ludtke R, Werner M, Huber R. In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals. Eur J Med Res 2002;7(4): 155-163.
[22]  Heinzerling L, Von BV, Liebenthal C, Von BR, Volk HD. Immunologic Effector Mechanisms of a Standardized Mistletoe Extract on the Function of Human Monocytes and Lymphocytes in vitro, ex vivo, and in vivo. Journal of Clinical Immunology 2006; Jul 26(4): 347-59
[23]  Antony VB, Godbey SW, Kunkel SL, et al. Recruitment of inflammatory cells to the pleural space: chemotactic cytokines, IL-8, and monocyte chemotactic peptide-1 in human pleural fluids. J Immunol 1993; 151: 7216-7223.
[24]  Antony VB, Hott JW, Kunkel SL, Godbey SW, Burdick MD, Strieter RM. Pleural mesothelial cell expression of C-C (monocyte chemotactic peptide) and C-X-C (interleukin 8) chemokines. Am J Respir Cell Mol Biol 1995; 12: 581-588.
[25]  Rodriguez-Panadero F, Segado A, Martin Juan J, Ayerbe R, Torres Garcia I, Castillo J. Failure of talc pleurodesis is associated with increased pleural fibrinolysis. Am J Respir Crit Care Med 1995; 151: 785-790.
[26]  Harrison LH Jr. In some cases - avoid talc pleurodesis. Chest 1995; 108: 289.
[27]  Balassoulis G, Sichletidis L, Spyratos D, Chloros D, Zarogoulidis K, Kontakiotis T, Bagalas V, Porpodis K, Manika K, Patakas D. Efficacy and safety of erythromycin as sclerosing agent in patients with recurrent malignant pleural effusion. Am J Clin Oncol. 2008 Aug; 31(4): 384-9.
[28]  Rodriguez-Panadero F, Lopez Mejias J. Low glucose and pH levels in malignant pleural effusions: diagnostic significance and prognostic value in respect to pleurodesis. Am Rev Respir Dis 1989; 139: 663-667.
[29]  Rodriguez-Panadero F, Sanchez Gil R, Martin Juan J, Castillo Gomez J.: Prediction of results of talc pleurodesis in malignant pleural effusions. Am J Respir Crit Care Med 1994; 149: (4, 2): A1103.